Corat Therapeutics

Executive Summary

Corat Therapeutics is a German biotechnology company headquartered in Hamburg, founded in 2018, that specializes in developing recombinant, fully human neutralizing antibodies as immunotherapies. The company's lead program targets SARS-CoV-2, with antibodies designed to both treat and prevent COVID-19 by immediately neutralizing the virus. Corat leverages a proprietary antibody phage display platform based on human gene libraries, enabling rapid identification and development of therapeutic candidates. While the COVID-19 pandemic has driven initial focus, the platform's versatility holds potential for expansion into other infectious diseases or oncology indications. As a private company with limited public disclosures, Corat operates in a competitive landscape dominated by established antibody developers and vaccines. However, its fully human antibody approach may offer advantages in safety and reduced immunogenicity. The company's ability to progress its pipeline and secure partnerships or funding will be critical for its near-term viability, especially given the shifting demand for COVID-19 therapeutics.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 1 clinical trial for lead SARS-CoV-2 antibody30% success
• TBDStrategic partnership or licensing deal for antibody platform40% success
• Q3 2026Award of German government grant for infectious disease research50% success